Infinity Pharma and Bristol-Myers Squibb add TNBC patients to clinical evaluation of IPI-549 and Opdivo

|About: Infinity Pharmaceutica... (INFI)|By:, SA News Editor

Infinity Pharmaceuticals (INFI +3.5%) and Bristol-Myers Squibb (BMY +0.3%) expand their clinical collaboration assessing the combination of IPI-549 and Opdivo (nivolumab) to include patients with triple negative breast cancer (TNBC) who have not been previously treated with a PD-1 or PD-L1 inhibitor.

TNBC patients are generally treatment-resistant with only a very few who respond to a checkpoint inhibitor.

IPI-549 is an orally available inhibitor of an enzyme called phosphoinositide-3-kinase (PI3K)-gamma that plays a key role in inflammation, immunity and cancer.

Previously: Infinity Pharma's lead product candidate IPI-549 shows encouraging results in preclinical cancer testing; shares ahead 21% (Jan. 20)

Subscribe for full text news in your inbox